Skip to main content
. 2019 Aug 9;12:6297–6307. doi: 10.2147/OTT.S214689

Figure 3.

Figure 3

MALAT1 directly targets miR-503-5p.

Notes: (A) The expressions of miR-503-5p in SKOV3 and OVCAR3 cells were determined in response to overexpression or knockdown of MALAT1 using reverse transcription-quantitative polymerase chain reaction analysis. (B) MALAT1 expression in response to miR-503-5p overexpression or miR-503-5p inhibition was determined by using real-time PCR. (C) Mimics NC/miR-503-5p mimics or inhibitor NC/miR-503-5p inhibitor was transfected into SKOV3 and OVCAR3 cells to achieve miR-503-5p overexpression or inhibition, verified by using real-time PCR. (D) A WT-MALAT1 luciferase reporter vector (WT-MALAT1) and a MT-MALAT1 luciferase reporter vector (MT-MALAT1) with mutations on miR-503-5p binding sites of the MALAT1 were constructed. (E) The WT-MALAT1/MT-MALAT1 vectors and miR-503-5p NC/miR-503-5p mimics/miR-503-5p inhibitor were co-transfected into SKOV3 and OVCAR3 cells. The luciferase activity of the MALAT1 luciferase reporter vector was determined. (F) Verification of the binding of MALAT1 and miR-503-5p determined by the pull-down assay using MALAT1 probe. (G) Verification of the binding of MALAT1 and miR-503-5p determined by the pull-down assay using miR-503-5p probe. Scram probe was used as negative control. Data are presented as the mean ± standard error of the mean (n=3). *P<0.05, **P<0.01, ***P<0.001  vs NC or blank control.

Abbreviations: MALAT1, metastasis-associated lung adenocarcinoma transcript 1; si-MALAT1, MALAT1 small interfering RNA; si-NC, noncoding small interfering RNA; NB, Northern blot.